2. Search Result
Search Result
Results for "

HbA1c

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Peptides

1

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P4070
    Insulin icodec

    		Insulin Receptor Metabolic Disease
    Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus [1] .
    Insulin icodec
  • HY-120565
    WB403

    		G protein-coupled Bile Acid Receptor 1 Metabolic Disease
    WB403 is an orally active TGR5 activator with an EC50 of 5.5 μM against human TGR5. WB403 activates TGR5 to stimulate downstream signaling pathways, promote GLP-1 secretion, improve glucose tolerance in mice with type 2 diabetes, and reduce levels of fasting blood glucose, postprandial blood glucose and HbA1c. WB403 increases pancreatic β-cell mass and restores the distribution of α-cells and β-cells in islets. WB403 is applicable to the research of type 2 diabetes [1].
    WB403
  • HY-19325
    SKI2852

    		11β-HSD Metabolic Disease
    SKI2852 is a potent, selective and orally active 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with IC50s of 1.6 nM and 2.9 nM against mHSD1 and hHSD1, respectively [1].
    SKI2852
  • HY-178780
    MKP10241

    		GPR119 Metabolic Disease
    MKP10241 is an orally active GPR119 agonist. MKP10241 elevates cAMP levels in the GPR119 expressing cell line (EC50: 3.7 nM). MKP10241 reduces blood glucose levels and HbA1c in acute models and a chronic diabetic mouse model. MKP10241 also demonstrates excellent preclinical efficacy in acute as well as chronic rodent models of obesity, and MASH [1].
    MKP10241
  • HY-117075
    BI-44847

    		SGLT Metabolic Disease
    BI-44847 is a selective and orally active SGLT2 inhibitor. BI-44847 can increase UGE and decrease HbA1c levels. BI-44847 shows improvement in fasting and fed glucose levels. BI-44847 can be studied in research on type 2 diabetes mellitus (T2DM) [1].
    BI-44847
  • HY-W751932
    Carboxy-EG6-undecanethiol

    		Biochemical Assay Reagents Others
    Carboxy-EG6-undecanethiol is an alkanethiol that suitable for self-assembly a gold thin-film substrate. Carboxy-EG6-undecanethiol can selectively capture HbA1c in sample by covalent coupling of 3-aminophenyl boronic acid (3-APBA) [1].
    Carboxy-EG6-undecanethiol
  • HY-E70375
    Fructosyl-peptide oxidase (FPOX-CE)

    Fructosyl-peptide: oxygen oxidoreductase

    		 Others Others
    Fructosyl-peptide oxidase (FPOX-CE) (Fructosyl-peptide: oxygen oxidoreductase) is an enzyme that catalyzes the oxidation of glycopeptides. Fructosyl-peptide oxidase (FPOX-CE) shows high activity against small molecule glycated peptides, but no activity is detected against the glycated hexapeptide standard fVHLTPE used in the study. Fructosyl-peptide oxidase (FPOX-CE) can be used in the study of diabetes monitoring [1].
    Fructosyl-peptide oxidase (FPOX-CE)
  • HY-P992007
    PF-06293620

    RN909

    		 GCGR Metabolic Disease
    PF-06293620 (RN909) is a monoclonal antibody antagonist of the glucagon receptor. PF-06293620 produces dose-dependent, durable lowering of fasting plasma glucose and reduces HbA1c levels. PF-06293620 can be used for the research of type 2 diabetes mellitus [1].
    PF-06293620
  • HY-17604
    Bexagliflozin
    1 Publications Verification

    EGT1442; EGT0001442; THR-1442

    		 SGLT Cardiovascular Disease Metabolic Disease
    Bexagliflozin (EGT1442) is an orally active and selective SGLT2 inhibitor with IC50 values of 0.002 μM and 5.6 μM for SGLT2 and SGLT1, respectively. Bexagliflozin selectively inhibits SGLT2-mediated sodium-dependent glucose uptake. Bexagliflozin induces saturable urinary glucose excretion in normal rats and dogs. Bexagliflozin reduces blood glucose and HbA1c levels in db/db mice without affecting body mass or insulin level. Bexagliflozin can be used for the research of type 2 diabetes mellitus, hypertensive stroke [1].
    Bexagliflozin
  • HY-P11736
    mcIRBP-9

    		NF-κB Metabolic Disease
    mcIRBP-9 is an orally bioavailable NF-κB inhibitor. mcIRBP-9 reduces the levels of TNF-α, IL-1β and TGF-β1 in renal tissues, and decreases LPS-induced IL-1β production. mcIRBP-9 can be used in research related to diabetic nephropathy and type 2 diabetes mellitus [1].
    mcIRBP-9
  • HY-153667
    MK-2305

    		Free Fatty Acid Receptor Metabolic Disease
    MK-2305 is an orally active GPR40 partial agonist with an EC50 of 6 nM in rats. MK-2305 mediates glucose-stimulated insulin secretion and inhibits endogenous glucose production by reducing gluconeogenesis from tricarboxylic acid (TCA) cycle substrates. MK-2305 increases plasma insulin levels under hyperglycemic and glucose-stimulated conditions, reduces fasting blood glucose, and improves glucose homeostasis. MK-2305 can be used in studies related to type 2 diabetes [1] .
    MK-2305

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: